Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes

Viral Immunology

Volumn 23, Issue 4, 2010, Pages 369-376

  Jarasch Althof, Nadine ^a   Wiesener, Nadine ^a   Schmidtke, Michaela ^a   Wutzler, Peter ^a   Henke, Andreas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; FC RECEPTOR; MEMBRANE PROTEIN; PROTEIN A;

ANIMAL CELL; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; B LYMPHOCYTE; CELL SEPARATION; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS RECOMBINANT; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; ANTIGENS, CD19; B-LYMPHOCYTES; CELLS, CULTURED; COXSACKIEVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENTEROVIRUS B, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE SERA; MALE; MICE; MICE, INBRED BALB C; RECEPTORS, VIRUS; VIRUS INTERNALIZATION; VIRUS PHYSIOLOGICAL PHENOMENA;

ADENOVIRIDAE; COXSACKIEVIRUS; MURINAE;

EID: 77955902642     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2010.0018     Document Type: Article

References (38)

1. Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, and McManus BM: Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol 1996;70: 4632-4645.
2. Chehadeh W, Bouzidi A, Alm G, Wattre P, and Hober D: Human antibodies isolated from plasma by affinity chromatography increase the coxsackievirus B4-induced synthesis of interferon-alpha by human peripheral blood mononuclear cells in vitro. J Gen Virol 2001;82:1899-1907.
3. Chehadeh W, Lobert PE, Sauter P, et al.: Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon. J Virol 2005;79:13882-13891.
4. Dotta F, Censini S, van Halteren AG, et al.: Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 2007;104:5115-5120.
5. Frisk G, Nilsson E, Ehrnst A, and Diderholm H: Enterovirus IgM detection: specificity of mu-antibody-capture radioimmunoassays using virions and procapsids of Coxsackie B virus. J Virol Methods 1989;24:191-202.
6. Fust G: Enhancing antibodies in HIV infection. Parasitology 1997;115(Suppl):S127-S140.
7. Gaunt CJ, Sakkinen P, Rose NR, and Huber SA: Picornaviruses: immunopathology and autoimmunity. In: Effects of Microbes on the Immune System. (Cunningham MW, and Fujinami RS, eds.). Lippincott-Raven: Philadelphia, 1999, pp. 313-329.
8. Girn J, Kavoosi M, and Chantler J: Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain. J Gen Virol 2002;83:351-358.
9. Gravanis MB, and Sternby NH: Incidence of myocarditis. A 10-year autopsy study from Malmo, Sweden. Arch Pathol Lab Med 1991;115:390-392.
10. Grist NR, Bell EJ, and Assaad F: Enteroviruses in human disease. Prog Med Virol 1978;24:114-157.
11. Gupta S, Markham DW, Drazner MH, and Mammen PP: Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 2008;5:693-706.
12. Halstead SB, and O'Rourke EJ: Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977;265: 739-741.
13. Hawkes RA: Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci 1964;42:465-482.
14. Henke A, Huber S, Stelzner A, and Whitton JL: The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 1995;69:6720-6728.
15. Henke A, Launhardt H, Klement K, Stelzner A, Zell R, and Munder T: Apoptosis in coxsackievirus B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva. J Virol 2000;74:4284-4290.
16. Henke A, Mohr C, Sprenger H, Graebner C, Stelzner A, Nain M, and Gemsa D: Coxsackievirus B3-induced production of tumor necrosis factor-alpha, IL- 1 beta, and IL-6 in human monocytes. J Immunol 1992;148:2270-2277.
17. Hober D, Chehadeh W, Bouzidi A, and Wattre P: Antibodydependent enhancement of coxsackievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon-alpha synthesis. J Infect Dis 2001;184: 1098-1108. (Pubitemid 33010461)
18. Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, and Osterhaus AD: Vaccine-induced enhancement of viral infections. Vaccine 2009;27:505-512.
19. Jarasch N, Martin U, Kamphausen E, Zell R, Wutzler P, and Henke A: Interferon-gamma-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3. Viral Immunol 2005;18: 355-364.
20. JaraschN,MartinU, Zell R,Wutzler P, andHenkeA: Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19+ B lymphocytes. Apoptosis 2007;12:1633-1643.
21. Kim KS, Hufnagel G, Chapman NM, and Tracy S: The group B coxsackieviruses and myocarditis. Rev Med Virol 2001; 11:355-368.
22. Kishimoto C, Kurokawa M, and Ochiai H: Antibodymediated immune enhancement in coxsackievirus B3 myocarditis. J Mol Cell Cardiol 2002;34:1227-1238.
23. Klingel K, McManus BM, and Kandolf R: Enterovirusinfected immune cells of spleen and lymph nodes in the murine model of chronic myocarditis: a role in pathogenesis? Eur Heart J 1995;16(Suppl O):42-45.
24. Knowlton KU, Jeon ES, Berkley N, Wessely R, and Huber S: A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 1996;70:7811-7818.
25. Magnani JW, and Dec GW: Myocarditis: current trends in diagnosis and treatment. Circulation 2006;113:876-890.
26. Matteucci D, Paglianti M, Giangregorio AM, Capobianchi MR,. Dianzani F, and Bendinelli M: Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J Virol 1985;56:651-654.
27. Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard J, and Whitton JL: The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol 1999;155:1205-1215.
28. Olsen CW, Corapi WV, Ngichabe CK, Baines JD, and Scott FW: Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol 1992; 66:956-965.
29. Salvetti M, Giovannoni G, and Aloisi F: Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 2009;22: 201-206.
30. Sauter P, and Hober D: Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect 2009;11:443-451.
31. Slifka MK, Pagarigan R, Mena I, Feuer R, and Whitton JL: Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol 2001;75:2377-2387.
32. Stoiber H, Soederholm A, Wilflingseder D, Gusenbauer S, Hildgartner A, and Dierich MP: Complement and antibodies: a dangerous liaison in HIV infection? Vaccine 2008;26(Suppl 8):I79-I85.
33. Takada A, Watanabe, K. Okazaki, H. Kida and Y. Kawaoka: Infectivity-enhancing antibodies to Ebola virus glycoprotein. J Virol 2001;75:2324-2330.
34. Vuorinen T, Vainionpaa R, Heino J, and Hyypia T: Enterovirus receptors and virus replication in human leukocytes. J Gen Virol 1999;80(Pt 4):921-927.
35. Vuorinen T, Vainionpaa R, Kettinen H, and Hyypia T: Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines. Blood 1994;84:823-829.
36. Vuorinen T, Vainionpaa R, Vanharanta, and Hyypia T: Susceptibility of human bone marrow cells and hematopoietic cell lines to coxsackievirus B3 infection. J Virol 1996; 70:9018-9023.
37. Wang J P, Asher DR, Chan M, Kurt-Jones EA, and Finberg RW: Cutting edge: Antibody-mediated TLR7- dependent recognition of viral RNA. J Immunol 2007;178: 3363-3367.
38. Zell R, Ihle Y, Seitz S, Gundel U, Wutzler P, and Gorlach M: Poly(rC)-binding protein 2 interacts with the oligo(rC) tract of coxsackievirus B3. Biochem Biophys Res Commun 2008;366:917-921.